Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ReShape Lifesciences (RSLS)
NASDAQ:RSLS
Holding RSLS?
Track your performance easily
RSLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.09 - $29.00
Previous CloseN/A
Volume8.33K
Average Volume (3M)23.25K
Market Cap
$3.24M
Enterprise Value$2.22M
Total Cash (Recent Filing)$3.31M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Mar 31, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.40
Shares Outstanding729,980
10 Day Avg. Volume28,786
30 Day Avg. Volume23,255
Standard Deviation0.36
R-Squared0.04
Alpha-0.10
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.39
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue0.27
Enterprise Value/Gross Profit0.40
Enterprise Value/Ebitda-0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ReShape Lifesciences News
PremiumCompany Announcements
ReShape Lifesciences Announces Merger and Asset Sale Plans
PremiumCompany Announcements
ReShape Lifesciences Reports Q3 Growth and Strategic Moves
Ownership Overview
11.57% Insiders
0.12% Mutual Funds
― Other Institutional Investors
88.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RSLS FAQ
What was ReShape Lifesciences’s price range in the past 12 months?
ReShape Lifesciences lowest stock price was $4.09 and its highest was $29.00 in the past 12 months.
What is ReShape Lifesciences’s market cap?
ReShape Lifesciences’s market cap is $3.24M.
When is ReShape Lifesciences’s upcoming earnings report date?
ReShape Lifesciences’s upcoming earnings report date is Mar 31, 2025 which is in 57 days.
How were ReShape Lifesciences’s earnings last quarter?
ReShape Lifesciences released its earnings results on Nov 14, 2024. The company reported -$3.024 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.024.
Is ReShape Lifesciences overvalued?
According to Wall Street analysts ReShape Lifesciences’s price is currently Overvalued.
Does ReShape Lifesciences pay dividends?
ReShape Lifesciences does not currently pay dividends.
What is ReShape Lifesciences’s EPS estimate?
ReShape Lifesciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ReShape Lifesciences have?
ReShape Lifesciences has 729,980 shares outstanding.
What happened to ReShape Lifesciences’s price movement after its last earnings report?
ReShape Lifesciences reported an EPS of -$3.024 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.354%.
Which hedge fund is a major shareholder of ReShape Lifesciences?
Currently, no hedge funds are holding shares in RSLS
---
Company Description
ReShape Lifesciences
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then remotely inflated. The company was founded on January 2, 2008 and is headquartered in Carlsbad, CA.
---
RSLS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive achievements, such as revenue growth, cost reductions, improved profit margins, and strategic agreements aimed at enhancing shareholder value. However, it also acknowledged challenges, such as the contraction in revenue over the nine-month period and competition from GLP-1 pharmaceuticals. Overall, the positive aspects slightly outweigh the negative trends.Read More>---
Technical Analysis
---